BCRX logo

BCRX BioCryst Pharmaceuticals, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$7.22
-0.10 (-1.37%)

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel, orally administered, small-molecule therapeutics. The company currently markets two key products: Peramivir injection: An intravenous neuraminidase inhibitor, sold under the brand names RAPIVAB, RAPIACTA, and PERAMIFLU, used for the treatment of acute uncomplicated influenza. ORLADEYO: An oral se…

Market Cap: $1.86Bwww.biocryst.com

Price

No data yet.

Social Signal Score

44
5d
—
30d
46
5 mentions
—
60d
43
7 mentions
—
90d
43
15 mentions
—
news: 15

Analyst Ratings

29 analysts
Buyconsensus
Strong Buy 0Buy 23Hold 6Sell 0Strong Sell 0
Avg price target$19+163.2%
Low $11Median $17High $29
Current Consensus

Revenue

$180.29M+1907.04%
$1.45M$136.48M$271.52M$406.56M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$0.14
$0.07–$0.29
3 analysts
FY2026
$-2.31-1744% YoY
$-2.44–$-2.15
4 analysts
FY2027
$0.53
$0.39–$0.67
5 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Charles K. Gayer
Sector
Healthcare
Industry
Biotechnology
Employees
435
Beta
0.51
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
-3.19
www.biocryst.com